Autopsy report · NCT06046248

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

“Lack of funding and slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Suspended: paused, and may or may not restart.
• 25 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

Northside Hospital, Inc.

Sponsor type

University, hospital or other

Conditions

Chronic Graft Versus Host Disease

Interventions

Belumosudil; Rituximab

Participants

25 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
  “Slow accrual and lack of funding” (97% match in meaning)
• Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer
  “due to slow accrual and lack of funding” (92% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (86% match in meaning)
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
  “funding issues and poor accrual” (86% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.